The 21st century revolution in CLL: Why this matters to patients

详细信息    查看全文

• 作者：Brian Koffman^a ; ^{Bkoffman@CLLSociety.org" class="auth_mail" title="E-mail the corresponding author} ; Andrew Schorr^b
• 关键词：CLL ; Chronic lymphocytic leukaemia ; Patients ; Advocates ; Clinical trials ; Internet ; CLLSociety.org ; PatientPower.info ; Novel therapies ; Equipoise ; Financial toxicity ; Chemo-immunotherapy ; Patient education and empowerment
• 刊名：Best Practice Research Clinical Haematology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：29
• 期：1
• 页码：122-132
• 全文大小：237 K

文摘

The 21st century has seen rapid, positive changes in the management of chronic lymphocytic leukaemia from the patient's perspective. New prognostic and predictive markers have ushered in the start of more precise and individualized therapy. For the first time, combined therapy [fludarabine, cyclophosphamide and rituximab] has been shown to prolong life significantly. Clinical trials have become more adaptive, faster and more patient friendly. Perhaps the greatest change of all is the development of novel oral agents (ibrutinib and idelalisib) and powerful monoclonal antibodies that offer robust and durable disease control. Finally, access to and understanding of these changes through an empowered and educated patient population has grown through live education forums and the Internet.